Similarly, 8 weeks’ neoadjuvant sunitinib (VEGFR and platelet-derived growth factor receptor [PDGFR] TKI) was safe and feasible in patients with locally advanced or metastatic ccRCC (median 21% reduction in primary renal tumour diameter; PR 29%)17. This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.